LOGIN  |  REGISTER
Viking Therapeutics

embecta to Participate in Investor Events

May 01, 2024 | Last Trade: US$14.62 0.43 -2.86

PARSIPPANY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management will participate in the following investor events:

2024 BofA Securities Healthcare Conference

  • Management will host a fireside session on Thursday, May 16, 2024, at 10:00 a.m. Pacific Time (PT) at the Encore Hotel in Las Vegas. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at https://investors.embecta.com.

2024 Jefferies Global Healthcare Conference

  • Management will host a fireside session on Wednesday, June 5, 2024, at 5:30 p.m. Eastern Time (ET) at the Marriott Marquis in New York. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at https://investors.embecta.com.

2024 Truist Securities MedTech Conference

  • Management will host one-on-one investor meetings on Tuesday, June 18, 2024, at the InterContinental Hotel in Boston.

2024 Stifel’s Inaugural ADA Diabetes Tech Summit

  • Management will host a fireside session on Friday, June 21, 2024, in Orlando.

About embecta 

embecta is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.

Contacts:

MediaInvestors 
Christian GlazarPravesh Khandelwal
Sr. Director, Corporate CommunicationsVP, Head of Investor Relations
908-821-6922551-264-6547
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
Chimerix

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB